Any current/future new fundraising through debt or equity?

The company does not explicitly mention any current or upcoming fundraising through debt or equity in the provided transcripts. Capex guidance for FY '27 is between INR 200 crores to INR 225 crores, which is lower than last year's INR 296 crores, indicating projects are nearing completion. There is no mention of plans for additional QIPs (Qualified Institutional Placements) or debt issuances. The focus appears to be on organic growth, capacity utilization, and operational efficiencies rather than on raising fresh capital. However, the company is pushing for automation to mitigate wage increase

Any current/future capex/capital investment/strategic investment?

Poly Medicure Limited plans capex of INR 200 crores to INR 225 crores for FY '27, which is lower than last year's INR 296 crores. Most capex projects from previous years are getting ready and operational. Current focus is on automation to mitigate wage revisions and improve efficiencies. The company is heavily investing in infrastructure and product development in areas like cardiology, orthopedics, oncology, and renal care. New product launches include indigenously developed drug-eluting balloons and high-value products priced between INR 1 lakh to INR 10 lakh. Strategic acquisitions (Citieff

Future growth expectations in sales/revenue/volumes?

FY '27 consolidated revenue guidance: INR 2,300 to 2,400 crores, up from INR 1,875 crores in FY '26. Stand-alone revenue guidance: INR 1,900 to 1,950 crores, with domestic business expected to grow over 20% and international business over 15%. Export growth expected to recover with new product launches in the U.S. and added distributors in Europe. Strategic focus on higher-priced segments like orthopaedics, cardiology, neonatology, oncology, and renal care expected to improve margins and revenue mix. Expect a sustained shift from infusion therapy revenue share decreasing to around 50%, with hi

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects consolidated revenue of INR 2,300-2,400 crores in FY '27, up from INR 1,875 crores in FY '26, indicating ~25% growth. Standalone revenue guidance is INR 1,900-1,950 crores, with domestic business growing over 20% and international business over 15%. Standalone EBITDA margin is expected to be between 25%-27%, consistent with FY '26. Consolidated EBITDA margin guidance is 23%-25%. Growth drivers include ramp-up of high-technology products in cardiology, orthopedics, oncology, and renal care. Focus on import substitution and innovation with over 399 patents underpin future pro

IN US

Sale is live|00:00:00left today

Poly Medicure LtdQ1 FY26Healthcare Equipment & Supplies

Poly Medicure Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,650P/E: 43.5Market Cap: ₹15.3K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→FY '27 consolidated revenue guidance: INR 2,300 to 2,400 crores, up from INR 1,875 crores in FY '26.
→Stand-alone revenue guidance: INR 1,900 to 1,950 crores, with domestic business expected to grow over 20% and international business over 15%.
→Export growth expected to recover with new product launches in the U.S. and added distributors in Europe.
→Strategic focus on higher-priced segments like orthopaedics, cardiology, neonatology, oncology, and renal care expected to improve margins and revenue mix.
→Expect a sustained shift from infusion therapy revenue share decreasing to around 50%, with higher technology segments exceeding 50% revenue contribution.
→Growth drivers include domestic import substitution, insurance penetration in India, direct market access in US, Europe, Brazil, and ongoing product innovation.
→Management confident of 15-17% sustainable organic growth over next 3-5 years excluding acquisitions.

Margin guidance

Category 3

→The company expects consolidated revenue of INR 2,300-2,400 crores in FY '27, up from INR 1,875 crores in FY '26, indicating ~25% growth.
→Standalone revenue guidance is INR 1,900-1,950 crores, with domestic business growing over 20% and international business over 15%.
→Standalone EBITDA margin is expected to be between 25%-27%, consistent with FY '26.
→Consolidated EBITDA margin guidance is 23%-25%.
→Growth drivers include ramp-up of high-technology products in cardiology, orthopedics, oncology, and renal care.
→Focus on import substitution and innovation with over 399 patents underpin future profitability.
→Export growth will benefit from easing logistics, increased presence in U.S. and European markets, and expanded distributor network.
→Management believes worst disruptions are behind and sees sustainable organic growth in the mid-teens excluding acquisitions over the next 3-5 years.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company does not explicitly mention any current or upcoming fundraising through debt or equity in the provided transcripts.
→Capex guidance for FY '27 is between INR 200 crores to INR 225 crores, which is lower than last year's INR 296 crores, indicating projects are nearing completion.
→There is no mention of plans for additional QIPs (Qualified Institutional Placements) or debt issuances.
→The focus appears to be on organic growth, capacity utilization, and operational efficiencies rather than on raising fresh capital.
→However, the company is pushing for automation to mitigate wage increases, suggesting internal resource allocation rather than external fund raising.

Order book

The transcript does not specifically mention the current or expected order book or pending orders for Poly Medicure Limited. However, related insights include: - Business is described as "adequately positioned for growth ahead," indicating a positive outlook on order intake. - The company targets over 20% growth in the Renal segment and over 15% growth in the international business. - There is a focus on expanding market share, adding distributors in Europe and the U.S., suggesting a pipeline of orders. - The B2B nature of the business leads to quarter-on-quarter sales variations by geography, with preference to analyse on a full-year basis. - No explicit mention of pending or backlog orders was made in the calls on pages 6 to 17. Thus, while growth expectations and operational capacity are highlighted, exact order book figures or pending orders are not provided.

Capex plans

Yes

→Poly Medicure Limited plans capex of INR 200 crores to INR 225 crores for FY '27, which is lower than last year's INR 296 crores.
→Most capex projects from previous years are getting ready and operational.
→Current focus is on automation to mitigate wage revisions and improve efficiencies.
→The company is heavily investing in infrastructure and product development in areas like cardiology, orthopedics, oncology, and renal care.
→New product launches include indigenously developed drug-eluting balloons and high-value products priced between INR 1 lakh to INR 10 lakh.
→Strategic acquisitions (Citieffe, PendraCare, and a Brazil-based storage/distribution company) are in process with plans to integrate global supply chains and manufacturing.
→Cost-saving projects and efforts to shift some manufacturing to India are underway to improve margins in recently acquired companies.
→The infrastructure is being continuously strengthened to position the company for growth.

How does Poly Medicure Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

1Poly Medicure Ltd

Rev 3Mar 3

See full Healthcare Equipment & Supplies sector rankings

Want more stocks like Poly Medicure Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio